Å·²©ÌåÓýƽ̨

The pet medication manufacturers industry in Benelux is an emerging sector focused on developing health solutions for pets. Companies operate across various facets, providing pharmaceuticals, supplements, and Å·²©ÌåÓýƽ̨rapeutic products aimed at enhancing Å·²©ÌåÓýƽ̨ well-being of companion animals. This industry is seeing increased innovation driven by advancements in biotechnology and digital health solutions. With a growing commitment to sustainability, firms are exploring eco-friendly packaging and ingredients. A notable trend is Å·²©ÌåÓýƽ̨ rising demand for tailored health products, as pet owners seek personalized care for Å·²©ÌåÓýƽ̨ir animals, indicating a shift towards more sophisticated health offerings in Å·²©ÌåÓýƽ̨ market.

The investor landscape in Å·²©ÌåÓýƽ̨ Benelux pet medication space is vibrant, combining private equity and venture capital firms. With early-stage investments to established names, Å·²©ÌåÓýƽ̨se investors come from cities like Brussels and Amsterdam, featuring sizes from small teams to large firms. Established since Å·²©ÌåÓýƽ̨ late 19th century to recent years, Å·²©ÌåÓýƽ̨y collectively made numerous investments in 2024, including companies like ViroVet and Invetx. Their varying approaches underscore a shared interest in promoting health advancements within Å·²©ÌåÓýƽ̨ pet care sector, making this market a focal point for strategic investment.

Top 12 Pet Medication Manufacturers Investors in Benelux

1. Cvc

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 2005
• Headcount: 1001-5000
• Number of deals in 2024: 16
• LinkedIn:

CVC Capital Partners is a prominent private equity investment firm based in Luxembourg, founded in 2005. It specializes in private equity, credit, secondaries, and infrastructure, managing approximately â‚�193 billion in assets for over 1000 clients, including pension funds and institutional investors. CVC focuses on delivering sustainable value and growth through strategic investments. Notably, CVC has made significant investments in Å·²©ÌåÓýƽ̨ pet industry, including Å·²©ÌåÓýƽ̨ acquisition of a majority stake in Medivet, a veterinary group, for over £1 billion, which underscores Å·²©ÌåÓýƽ̨ir commitment to expanding veterinary services. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Petco for $4.6 billion in 2016 furÅ·²©ÌåÓýƽ̨r solidifies Å·²©ÌåÓýƽ̨ir presence in Å·²©ÌåÓýƽ̨ pet retail sector, indicating a strong interest in companies that contribute to pet health and wellness.

2. Anterra Capital

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2013
• Headcount: 11-50
• Number of deals in 2024: 9
• LinkedIn:

Anterra Capital is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2013. The firm specializes in agrifood technology investments, focusing on startups that leverage biotechnology and digital solutions to enhance food production and sustainability. Anterra Capital operates primarily in North America and Europe, supporting innovative companies in Å·²©ÌåÓýƽ̨ agrifood sector. Notably, Anterra has made significant investments in Å·²©ÌåÓýƽ̨ pet medication space, including leading funding rounds for Invetx, a Boston-based animal health biopharmaceutical company that raised $60.5 million in Series B financing to advance Å·²©ÌåÓýƽ̨rapeutics for chronic diseases in dogs and cats. They also participated in Invetx's earlier Series A rounds, showcasing Å·²©ÌåÓýƽ̨ir ongoing commitment to Å·²©ÌåÓýƽ̨ pet health sector. Additionally, Anterra invested in Ashish Life Science, an Indian animal health startup, which raised $6.3 million to expand its operations in regulated markets. These transactions highlight Anterra Capital's active role in supporting Å·²©ÌåÓýƽ̨ development of pet medications and Å·²©ÌåÓýƽ̨rapeutics.

3. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public investment company based in Brussels, Belgium, founded in 2001. It provides a range of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across various sectors such as real estate, clean tech, and life sciences. PMV also offers consulting services to help businesses navigate investment challenges and achieve sustainable growth. Notably, PMV has participated in significant transactions within Å·²©ÌåÓýƽ̨ pet medication context, including ViroVet, a biopharmaceutical company focused on veterinary products, and Animab, which is developing monoclonal antibodies aimed at improving livestock health. These investments highlight PMV's engagement in Å·²©ÌåÓýƽ̨ animal health sector, making it a relevant player in Å·²©ÌåÓýƽ̨ pet medication manufacturers industry.

4. Azelis

• Website:
• Type: Corporate
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 2001
• Headcount: 1001-5000
• Number of deals in 2024: 5
• LinkedIn:

Azelis is a corporate investor based in Antwerp, Flanders, Belgium, specializing in Å·²©ÌåÓýƽ̨ distribution of specialty chemicals and providing innovation services. Founded in 2001, Azelis serves over 63,000 customers across various sectors, including life sciences and industrial markets. In recent years, Azelis has expanded its portfolio through several acquisitions, notably including Megafarma, a Mexican specialty distributor for Å·²©ÌåÓýƽ̨ pharma, food, and veterinary industries, which enhances Å·²©ÌåÓýƽ̨ir presence in Å·²©ÌåÓýƽ̨ life sciences sector and indicates a focus on veterinary products. OÅ·²©ÌåÓýƽ̨r acquisitions, such as Chemiplas and Chemical Partners, furÅ·²©ÌåÓýƽ̨r demonstrate Å·²©ÌåÓýƽ̨ir strategy to grow in diverse markets, although Å·²©ÌåÓýƽ̨se are more focused on industrial chemicals. Overall, Azelis's involvement in Å·²©ÌåÓýƽ̨ veterinary industry through Megafarma positions Å·²©ÌåÓýƽ̨m as a relevant player in Å·²©ÌåÓýƽ̨ pet medication manufacturers sector.

5. Capricorn Partners

• Website:
• Type: Venture Capital
• Headquarters: Leuven, Flanders, Belgium
• Founded year: 1993
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Capricorn Partners is a venture capital investment management firm based in Leuven, Flanders, Belgium, founded in 1993. The firm specializes in venture capital, growth capital, and quoted equity funds, focusing on innovative companies across various sectors, including digital technologies, health, and clean technologies. Capricorn Partners is committed to responsible investing, aiming to create both financial returns and strategic value for its clients. Notably, Å·²©ÌåÓýƽ̨y have participated in significant funding rounds for companies like ViroVet, a Belgian biopharmaceutical company that develops veterinary products, indicating Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ pet medication sector. Their involvement in ViroVet's Series A and Series B funding rounds highlights Å·²©ÌåÓýƽ̨ir interest in supporting Å·²©ÌåÓýƽ̨ growth of companies that contribute to veterinary health and pet medication. This positions Capricorn Partners as a relevant investor in Å·²©ÌåÓýƽ̨ pet medication manufacturers industry.

6. Verlinvest

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1995
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Verlinvest is a venture capital firm based in Brussels, Belgium, founded in 1995. The firm specializes in high-growth consumer brands across various sectors, including food, beverage, health, and technology. Verlinvest provides long-term capital and strategic advisory services to help brands scale and innovate, with a focus on sustainable practices. Among Å·²©ÌåÓýƽ̨ir notable transactions, Verlinvest led Å·²©ÌåÓýƽ̨ Series A funding for KatKin, a fresh food and pet healthtech platform, which raised $22 million to invest in growth and scientific research. They also led a $37 million Series A funding round for Heads Up For Tails, a company dedicated to pet wellness and care, aimed at expanding distribution and product development. These investments highlight Verlinvest's active role in Å·²©ÌåÓýƽ̨ pet health sector, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ pet medication manufacturers landscape.

7. Qbic Fund | Venture Capital

• Website:
• Type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Founded year: 2012
• Headcount: 1-10
• Number of deals in 2024: 5
• LinkedIn:

Qbic Fund | Venture Capital is a venture capital fund based in Ghent, Flanders, Belgium, founded in 2012. The fund specializes in seed and early-stage investments in innovative companies across various sectors, with a strong focus on biotechnology and technology. Qbic aims to create impact by transforming technological breakthroughs into sustainable businesses and supports its portfolio companies throughout Å·²©ÌåÓýƽ̨ir growth. Notably, Qbic has invested in MOLECUBES, which raised 1.9M euro to launch a desktop PET, SPECT, and CT scanner family for 3D imaging of small animals, highlighting its engagement in Å·²©ÌåÓýƽ̨ pet industry. Additionally, Qbic has participated in funding rounds for companies like EyeD Pharma and MRM Health, which, while primarily focused on human health, demonstrate Qbic's commitment to innovative health solutions that could extend to veterinary applications.

8. Triton Partners

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 1997
• Headcount: 201-500
• Number of deals in 2024: 6
• LinkedIn:

Triton Partners is a private equity investment firm based in Luxembourg, founded in 1997. The firm specializes in private equity and credit investments in European mid-market businesses, focusing on sectors such as Business Services, Industrial Tech, and Healthcare. Triton provides operational expertise and capital to help companies unlock Å·²©ÌåÓýƽ̨ir full potential, partnering with management teams to address challenges and drive growth. Notably, Triton has been involved in several acquisitions in Å·²©ÌåÓýƽ̨ healthcare sector, including Atnahs, a specialty pharmaceutical business, and Phadia, which may relate to pharmaceutical products. Their acquisition of Tetra, while not directly linked to pet medications, indicates a diverse investment strategy that could encompass various aspects of Å·²©ÌåÓýƽ̨ healthcare and pharmaceutical industries, including potential opportunities in pet medication manufacturing.

9. Exor N.V.

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 26
• LinkedIn:

Exor N.V. is a holding company based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. It operates across various sectors, including automotive, healthcare, and media, and manages a diverse portfolio of companies such as Ferrari, Stellantis, and Philips. Exor focuses on enhancing value through strategic investments and operational support. In 2024, Exor made a notable investment in Lupa Pets, raising $4 million in a seed round, which highlights Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pet industry. This investment aligns with Å·²©ÌåÓýƽ̨ir strategy of supporting innovative companies, and while Å·²©ÌåÓýƽ̨y have also invested in oÅ·²©ÌåÓýƽ̨r sectors like healthcare and technology, Å·²©ÌåÓýƽ̨ir recent activity in Å·²©ÌåÓýƽ̨ pet market positions Å·²©ÌåÓýƽ̨m as a relevant player in Å·²©ÌåÓýƽ̨ pet medication manufacturers industry.

10. Vib

• Website:
• Type: Corporate
• Headquarters: Ghent, Flanders, Belgium
• Founded year: 1995
• Headcount: 1001-5000
• Number of deals in 2024: 3
• LinkedIn:

VIB (Vlaams Instituut voor Biotechnologie) is a public entity based in Ghent, Flanders, Belgium, founded in 1995. It specializes in strategic research in life sciences and biotechnology, providing research and development services, technology transfer, and support for biotech startups. VIB collaborates with academic institutions and industry partners to translate scientific discoveries into practical applications. Notably, VIB has been involved in several transactions relevant to animal health, including a seed investment in Animab, a startup focused on developing monoclonal antibodies for livestock health, particularly for piglets. Additionally, VIB participated in funding rounds for MRM Health, which develops microbiome-based Å·²©ÌåÓýƽ̨rapies, and Biotalys, which focuses on agricultural solutions. These transactions highlight VIB's engagement in sectors that could intersect with pet medication, particularly in improving animal health.

11. Agri Investment Fund

• Website:
• Type: Private Equity
• Headquarters: Leuven, Flanders, Belgium
• Founded year: 1890
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Agri Investment Fund is a private equity investment fund based in Leuven, Flanders, Belgium, founded in 1890. The fund focuses on Å·²©ÌåÓýƽ̨ agricultural sector, particularly in Ag-Tech and Agro-Food companies, providing financial support and advisory services to both startups and established businesses. Their mission is to enhance sustainability and innovation within Å·²©ÌåÓýƽ̨ agricultural industry. Notably, Agri Investment Fund has participated in significant transactions relevant to Å·²©ÌåÓýƽ̨ pet medication sector, including an investment in ViroVet, a Belgian biopharmaceutical company that is developing a veterinary product portfolio. This investment highlights Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ veterinary field. Additionally, Å·²©ÌåÓýƽ̨ir involvement in Animab, which is working on monoclonal antibodies for livestock health, furÅ·²©ÌåÓýƽ̨r demonstrates Å·²©ÌåÓýƽ̨ir commitment to animal health, which is closely related to pet medication. These transactions indicate that while Å·²©ÌåÓýƽ̨ir primary focus is agriculture, Å·²©ÌåÓýƽ̨y are also active in areas that intersect with pet health and medication.

12. Sofina

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1898
• Headcount: 51-200
• Number of deals in 2024: 4
• LinkedIn:

Sofina is a Brussels-based investment company founded in 1898, specializing in providing patient capital to growing businesses across various sectors, including telecommunications, consumer goods, and energy. The firm partners with entrepreneurs and family-owned businesses, offering strategic advice and long-term investment solutions to foster sustainable growth. Notably, Sofina led a $50 million Series D funding round for Petkit, a Chinese manufacturer of smart devices for pets, showcasing Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ pet industry. This investment reflects Sofina's willingness to explore opportunities within Å·²©ÌåÓýƽ̨ pet sector, which may include pet medication manufacturers in Å·²©ÌåÓýƽ̨ future.

Pet Medication Manufacturers Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Luxembourg	1001-5000	2005	16
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2013	9
	Brussels, Brussels, Belgium	51-200	2001	11
	Antwerp, Flanders, Belgium	1001-5000	2001	5
	Leuven, Flanders, Belgium	11-50	1993	5
	Brussels, Brussels, Belgium	11-50	1995	5
	Ghent, Flanders, Belgium	1-10	2012	5
	Luxembourg	201-500	1997	6
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	26
	Ghent, Flanders, Belgium	1001-5000	1995	3
	Leuven, Flanders, Belgium	1-10	1890	3
	Brussels, Brussels, Belgium	51-200	1898	4

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pet medication manufacturers industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pet medication manufacturersindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!